ArticleInternational journal of pharmaceutics: X2025
Nebulized macrophage membrane-engineered triptolide liposomes for Siglec-10/CD24-mediated therapeutic targeting in lung cancer.
Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) currently stands as the predominant etiological factor underlying lung cancer-related mortality on a global scale. Conventional drug delivery methods are associated with significant toxic side effects, highlighting the necessity to develop novel targeted delivery systems to improve the therapeutic efficacy of lung cancer treatment. Here, we aimed to develop a pulmonary drug delivery system for triptolide (TP) to treat orthotopic lung cancer. Herein, triptolide-loaded liposomes (TP-lip) were prepared to reduce the toxicity and improve the solubility of triptolide. Macrophage membranes (MM), rich in Siglec-10, were engineered onto the liposomes to enhance the tumor targeting through specific binding to Cluster of differentiation 24 (CD24), a molecule overexpressed on lung tumor cells. Regardless of macrophage polarization, the high Siglec-10 expression on cell membranes ensures effective tumor cell targeting. After modifying different types of MMs on TP-lip and nebulizing them, the aerodynamic fine particle fraction (FPF) of TP formulations exceeded 50%, and the mass median aerodynamic diameter (MMAD) was below 5 μm, suitable for pulmonary delivery. MM-modified liposomes showed higher cellular uptake and stronger inhibitory effects on LLC lung tumor cells. Pharmacokinetic studies showed that intratracheal administration (aerosolized drug delivery) of MM-lip could reduce the systemic drug exposure compared to intravenous injection, while achieving effective accumulation in lung tissues. Pulmonary delivery of M0-TP-lip significantly enhanced the anti-tumor efficacy and improved the lifespan of orthotopic lung tumor-bearing mice, with no apparent systemic toxicity observed. Overall, this highlights the potential of inhalable, biomimetic triptolide loaded liposomes for pulmonary tumor treatment through Siglec-10-mediated targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.